Cargando…

Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance—A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting

Objective: Over the last decade, active surveillance (AS) of low-risk prostate cancer has been increasing. The mpMRI fusion-guided biopsy of the prostate (FBx) is considered to be the gold standard in preoperative risk stratification. However, the role of FBx remains unclear in terms of risk stratif...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebner, Benedikt, Apfelbeck, Maria, Pyrgidis, Nikolaos, Nellessen, Tobias, Ledderose, Stephan, Pfitzinger, Paulo Leonardo, Volz, Yannic, Berg, Elena, Enzinger, Benazir, Rodler, Severin, Atzler, Michael, Ivanova, Troya, Clevert, Dirk-André, Stief, Christian Georg, Chaloupka, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952076/
https://www.ncbi.nlm.nih.gov/pubmed/36829741
http://dx.doi.org/10.3390/bioengineering10020247
_version_ 1784893540295245824
author Ebner, Benedikt
Apfelbeck, Maria
Pyrgidis, Nikolaos
Nellessen, Tobias
Ledderose, Stephan
Pfitzinger, Paulo Leonardo
Volz, Yannic
Berg, Elena
Enzinger, Benazir
Rodler, Severin
Atzler, Michael
Ivanova, Troya
Clevert, Dirk-André
Stief, Christian Georg
Chaloupka, Michael
author_facet Ebner, Benedikt
Apfelbeck, Maria
Pyrgidis, Nikolaos
Nellessen, Tobias
Ledderose, Stephan
Pfitzinger, Paulo Leonardo
Volz, Yannic
Berg, Elena
Enzinger, Benazir
Rodler, Severin
Atzler, Michael
Ivanova, Troya
Clevert, Dirk-André
Stief, Christian Georg
Chaloupka, Michael
author_sort Ebner, Benedikt
collection PubMed
description Objective: Over the last decade, active surveillance (AS) of low-risk prostate cancer has been increasing. The mpMRI fusion-guided biopsy of the prostate (FBx) is considered to be the gold standard in preoperative risk stratification. However, the role of FBx remains unclear in terms of risk stratification of low-risk prostate cancer outside high-volume centers. The aim of this study was to evaluate adverse pathology after radical prostatectomy (RP) in a real-world setting, focusing on patients diagnosed with Gleason score (GS) 6 prostate cancer (PCa) and eligible for AS by FBx. Subjects and Methods: Between March 2015 and March 2022, 1297 patients underwent FBx at the Department of Urology, Ludwig-Maximilians-University of Munich, Germany. MpMRI for FBx was performed by 111 different radiology centers. FBx was performed by 14 urologists from our department with different levels of experience. In total, 997/1297 (77%) patients were diagnosed with prostate cancer; 492/997 (49%) of these patients decided to undergo RP in our clinic and were retrospectively included. Univariate and multivariable logistic regression analyses were performed to evaluate clinical and histopathological parameters associated with adverse pathology comparing FBx and RP specimens. To compare FBx and systematic randomized biopsies performed in our clinic before introducing FBx (SBx, n = 2309), we performed a propensity score matching on a 1:1 ratio, adjusting for age, number of positive biopsy cores, and initial PSA (iPSA). Results: A total of 492 patients undergoing FBx or SBx was matched. In total, 55% of patients diagnosed with GS 6 by FBx were upgraded to clinically significant PCa (defined as GS ≥ 7a) after RP, compared to 52% of patients diagnosed by SBx (p = 0.76). A time delay between FBx and RP was identified as the only correlate associated with upgrading. A total of 5.9% of all FBx patients and 6.1% of all SBx patients would have been eligible for AS (p > 0.99) but decided to undergo RP. The positive predictive value of AS eligibility (diagnosis of low-risk PCa after biopsy and after RP) was 17% for FBx and 6.7% for SBx (p = 0.39). Conclusions: In this study, we show, in a real-world setting, that introducing FBx did not lead to significant change in ratio of adverse pathology for low-risk PCa patients after RP compared to SBx.
format Online
Article
Text
id pubmed-9952076
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99520762023-02-25 Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance—A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting Ebner, Benedikt Apfelbeck, Maria Pyrgidis, Nikolaos Nellessen, Tobias Ledderose, Stephan Pfitzinger, Paulo Leonardo Volz, Yannic Berg, Elena Enzinger, Benazir Rodler, Severin Atzler, Michael Ivanova, Troya Clevert, Dirk-André Stief, Christian Georg Chaloupka, Michael Bioengineering (Basel) Article Objective: Over the last decade, active surveillance (AS) of low-risk prostate cancer has been increasing. The mpMRI fusion-guided biopsy of the prostate (FBx) is considered to be the gold standard in preoperative risk stratification. However, the role of FBx remains unclear in terms of risk stratification of low-risk prostate cancer outside high-volume centers. The aim of this study was to evaluate adverse pathology after radical prostatectomy (RP) in a real-world setting, focusing on patients diagnosed with Gleason score (GS) 6 prostate cancer (PCa) and eligible for AS by FBx. Subjects and Methods: Between March 2015 and March 2022, 1297 patients underwent FBx at the Department of Urology, Ludwig-Maximilians-University of Munich, Germany. MpMRI for FBx was performed by 111 different radiology centers. FBx was performed by 14 urologists from our department with different levels of experience. In total, 997/1297 (77%) patients were diagnosed with prostate cancer; 492/997 (49%) of these patients decided to undergo RP in our clinic and were retrospectively included. Univariate and multivariable logistic regression analyses were performed to evaluate clinical and histopathological parameters associated with adverse pathology comparing FBx and RP specimens. To compare FBx and systematic randomized biopsies performed in our clinic before introducing FBx (SBx, n = 2309), we performed a propensity score matching on a 1:1 ratio, adjusting for age, number of positive biopsy cores, and initial PSA (iPSA). Results: A total of 492 patients undergoing FBx or SBx was matched. In total, 55% of patients diagnosed with GS 6 by FBx were upgraded to clinically significant PCa (defined as GS ≥ 7a) after RP, compared to 52% of patients diagnosed by SBx (p = 0.76). A time delay between FBx and RP was identified as the only correlate associated with upgrading. A total of 5.9% of all FBx patients and 6.1% of all SBx patients would have been eligible for AS (p > 0.99) but decided to undergo RP. The positive predictive value of AS eligibility (diagnosis of low-risk PCa after biopsy and after RP) was 17% for FBx and 6.7% for SBx (p = 0.39). Conclusions: In this study, we show, in a real-world setting, that introducing FBx did not lead to significant change in ratio of adverse pathology for low-risk PCa patients after RP compared to SBx. MDPI 2023-02-13 /pmc/articles/PMC9952076/ /pubmed/36829741 http://dx.doi.org/10.3390/bioengineering10020247 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ebner, Benedikt
Apfelbeck, Maria
Pyrgidis, Nikolaos
Nellessen, Tobias
Ledderose, Stephan
Pfitzinger, Paulo Leonardo
Volz, Yannic
Berg, Elena
Enzinger, Benazir
Rodler, Severin
Atzler, Michael
Ivanova, Troya
Clevert, Dirk-André
Stief, Christian Georg
Chaloupka, Michael
Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance—A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting
title Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance—A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting
title_full Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance—A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting
title_fullStr Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance—A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting
title_full_unstemmed Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance—A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting
title_short Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance—A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting
title_sort adverse pathology after radical prostatectomy of patients eligible for active surveillance—a summary 7 years after introducing mpmri-guided biopsy in a real-world setting
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952076/
https://www.ncbi.nlm.nih.gov/pubmed/36829741
http://dx.doi.org/10.3390/bioengineering10020247
work_keys_str_mv AT ebnerbenedikt adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT apfelbeckmaria adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT pyrgidisnikolaos adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT nellessentobias adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT ledderosestephan adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT pfitzingerpauloleonardo adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT volzyannic adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT bergelena adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT enzingerbenazir adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT rodlerseverin adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT atzlermichael adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT ivanovatroya adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT clevertdirkandre adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT stiefchristiangeorg adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting
AT chaloupkamichael adversepathologyafterradicalprostatectomyofpatientseligibleforactivesurveillanceasummary7yearsafterintroducingmpmriguidedbiopsyinarealworldsetting